Current issues in onychomycosis

Annals of Pharmacotherapy

Volumn 32, Issue 2, 1998, Pages 204-214

  Trépanier, Eric F ^a,b   Amsden, Guy W ^c,d  

^a Bassett Healthcare ^*  (United States)

^b Global Health Consulting Inc   (Canada)

^c BASSETT HEALTHCARE   (United States)

^d BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

Fluconazole; Itraconazole; Onychomycosis; Terbinafine

Indexed keywords

ASTEMIZOLE; CARBAMAZEPINE; CISAPRIDE; CYCLOSPORIN; FELODIPINE; FLUCONAZOLE; ITRACONAZOLE; MIDAZOLAM; PHENYTOIN; RIFABUTIN; RIFAMPICIN; TERBINAFINE; TERFENADINE; TRIAZOLAM; WARFARIN; ZIDOVUDINE;

COST EFFECTIVENESS ANALYSIS; DERMATOPHYTE; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MYCOLOGY; NAIL DISEASE; ONYCHOMYCOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; ONYCHOMYCOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 2642667457     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17006     Document Type: Review

References (114)

1. Scher RK. Onychomycosis is more than a cosmetic problem (editorial). Br J Dermatol 1994;130(suppl 43):15.
2. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone Inc., 1995:2375-86.
3. Hoffman AF, Driver VR. Onychomycosis. Clin Podiatr Med Surg 1996; 13:13-29.
4. Vobecky NJ. Superficial fungal infections: evolution of proprietary anti-fungal agents. Sandoz Continuing Education 1996;9(2):1-27.
5. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with Onychomycosis. Qual Life Res 1993;2:341-8.
6. Rezabek GH, Friedman AD. Superficial fungal infections of the skin: diagnosis and current treatment recommendations. Drugs 1992;43:674-82.
7. Denning DW, Evans EGV, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). BMJ 1995;311:1277-81.
8. Elewski BE, Roderick JH. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996;23:305-13.
9. McCarthy DJ. Origins of onychomycosis. Clin Podiatr Med Surg 1995; 12:221-49.
10. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:165.
11. Dompmartin D, Dompmartin A, Deluol AM, Grosshans E, Coulaud JP. Onychomycosis and AIDS. Clinical and laboratory findings in 62 patients. Int J Dermatol 1990;29:337-9.
12. Staughton R. Skin manifestations in AIDS patients. Br J Clin Pract 1990;71(suppl):109-13.
13. Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Ann Acad Med Singapore 1995;24:528-33.
14. Lagana FJ. Nondermatophytes: pathogen or distractor in onychomycosis. Clin Podiatr Med Surg 1995;12:255-62.
15. Midgley G, Moore MK, Cook JC, Phan QG. Mycology of nail disorders. J Am Acad Dermatol 1994;31(3, part 2):S68-74.
16. Greer DL. Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 1995;34:521-4.
17. Ellis DH, Watson AB, Marley JE, Williams TG. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997;136:490-3.
18. Daniel CR, Elewski BE. Candida as a nail pathogen in healthy patients. J Miss State Med Assoc 1995;36:379-81.
19. Nolting S, Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994;130 (suppl 43):16-21.
20. Faergemann J. The role of yeasts in onychomycosis. Mycoses 1996;39: 223-4.
21. Zaias N. Onychomycosis. Arch Dermatol 1972;105:263-74.
22. Odom RB. New therapies for onychomycosis. J Am Acad Dermatol 1996;35(suppl):S26-30.
23. Terbinafine for onychomycosis. Med Lett Drugs Ther 1996;38:72-4.
24. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994;31(suppl):S78-81.
25. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29(suppl):S50-4.
26. Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 1986;3:399-406.
27. Clissold SP. Safety in clinical practice. In: Jones HE, ed. Ketoconazole today. Auckland, New Zealand: ADIS Press, 1990:77-91.
28. Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 25:398-400.
29. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84.
30. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996;51:585-620.
31. Bennett JE. Antimicrobial agents: antifungal agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th edition. New York, NY: McGraw-Hill, 1996:1175-90.
32. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
33. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995;50: 658-90.
34. Shear NH, Gupta AK. Terbinafine for the treatment of onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 1995; 131:937-42.
35. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992;126(suppl 39):28-32.
36. Matthieu L, De Doncker P, Cauwenbergh G, Woestenborghs R, Van de Velde V, Janssen PAJ, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed - an investigation in onychomycosis. Clin Exp Dermatol 1991;16:374-6.
37. Product information. Diflucan (fluconazole). New York: Pfizer Pharmaceuticals, January 1997.
38. Hay RJ. Pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1994;31(suppl):S78-81.
39. Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol 1996;35: 216-9.
40. Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly. Acta Derm Venereol 1996;76:219-21.
41. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, et al. Posttreatment itraconazole levels in the nail: new implications for treatment of onychomycosis. J Am Acad Dermatol 1992;26:731-5.
42. Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol 1994;31(suppl):S87-90.
43. Jensen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treat 1990;1(suppl 2):15-8.
44. Arenas R, Dominguez-Cherit J, Femandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-43.
45. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 1996;134(suppl 46):16-7.
46. Bräutigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection (published erratum appears in BMJ 1995;311:1350). BMJ 1995;311:919-22.
47. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992;304:1151-4.
48. Van der Schroeff JG, Cirkel PKS, Crijns MB, Van Dijk TJA, Govaert FJ, Groeneweg DA, et al. A randomised treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126(suppl 39):36-9.
49. Watson A, Marley J, Ellis D, Williams T. Terbinafme in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995;33: 775-9.
50. Hofmann H, Bräutigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995;131:919-22.
51. Faergemann J, Anderson C, Hersle K, Hradil E, Nordin P, Kaaman T, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995;32:750-3.
52. Tosti A, Piraccini BM, Stinchi C, Venturo N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996;34:595-600.
53. De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.
54. Havu V, Brandt H, Heikkilae H, Hollmen A, Oksman R, Rantanen T, et al. A double-blind, randomised study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997;136:230-4.
55. Odom RB, Lay R, Scher RK, Daniel R, Elewski BE, Zaias N, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997;36:231-5.
56. Hogan DJ. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995;33:541-2.
57. Haneke E, Tausch I, Bräutigam M, Weidinger G, Wetzel D, for the LA-GOS III Study Group. Short duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995;32:72-7.
58. Hay RJ, Clayton YM, Moore MK, Midgely G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988;119: 359-66.
59. Kim JA, Ann KJ, Kim JM, Youn JI. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995;56:1066-75.
60. Rongioletti F, Robert E, Tripodi S, Persi A. Treatment of onychomycosis with itraconazole. J Dermatol Treat 1992;2:145-6.
61. Haneke E, Delescluse J, Plinck EPB, Hay RJ. The use of itraconazole in onychomycosis. Eur J Dermatol 1996;6:7-10.
62. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis: open and double-blind studies. Acta Derm Venereol 1990;70:137-40.
63. Odom R, Daniel CR, Aly RA. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 1996;35:110-1.
64. Piepponen T, Blomqvist K, Brandt H, Havu V, Hollmen A, Kohtamaki K, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Agents Chemother 1992;29:195-205.
65. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991;30:586-9.
66. Koring HC, Schafer-Korting M, Zienicke H, Georgii A, Ollert MW. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993;37:2064-8.
67. Degreef H, De Doncker P, Joosen H, Peeters M, Heremans A. Randomized, double-blind trial on the efficacy and tolerability of itraconazole 200 mg compared with terbinafine 250 mg in the treatment of toenail onychomycosis (abstract). Proceedings of the American Academy of Dermatology 55th Annual Meeting, March 21-26, 1997, San Francisco, CA.
68. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992;128:909-10.
69. Nahass GT, Sisto M. Onychomycosis: successful treatment with onceweekly fluconazole. Dermatology 1993;186:59-61.
70. Smith SW, Sealy DP, Schneider E, Lackland D. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995;88:1217-20.
71. Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996;35:587-8.
72. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992;3:115-7.
73. Shuster S, Munro CS. Single dose treatment of fungal nail disease (letter). Lancet 1992;339:1066.
74. Bonifaz A, Carrasco-Gerard E, Saul A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol 1997;36:70-2.
75. Ginter G. Intermittent therapy with itraconazole - a new approach to the treatment of onychomycosis (abstract). Proceedings of the International Summit on Cutaneous Antifungal Therapy, November 10-13, 1994, Boston, MA.
76. Haneke E, Ring J, Tajerbashi D, De Doncker P, Heremans A. Efficacy and safety of itraconazole pulse therapy in the treatment of onychomycosis: an open German multicenter trial (abstract). Proceedings of the American Academy of Dermatology 54th Annual Meeting, February 10-15, 1996, Washington, DC.
77. Li WD, Ping WA, Yu LR, Wang R, De Doncker P, Heremans A. Therapeutic efficacy of intermittent pulse therapy with itraconazole in onychomycosis: a multicenter Chinese trial (abstract). Proceedings of the American Academy of Dermatology 54th Annual Meeting, February 10-15, 1996, Washington, DC.
78. FDC Rep 1996;58(51):T&G-20.
79. Wallace R, Piérard GE, De Doncker P. Experience with itraconazole in the treatment of nondermatophyte mold infections of the skin (abstract). Proceedings of the American Academy of Dermatology 55th Annual Meeting, March 21-26, 1997, San Francisco, CA.
80. Del Rosso JQ, Gupta AK. Oral antifungal agents: recognition and management of adverse reactions. Today's Therapeut Trends 1997;15:75-84.
81. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
82. Wahllander A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 1989;37:279-83.
83. Trépanier EF, Nafziger AN, Amsden GW. Terbinafine reduces theophylline clearance in healthy volunteers. Antimicrob Agents Chemother (in press).
84. Tarral A, Francheteau P, Guerret M. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers. Pharmacotherapy 1997; 17:791-5.
85. Guerret M, Francheteau P, Hubert M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 1997;17:767-73.
86. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995;40:270-2.
87. Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F, et al. Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 1994;102:740-3.
88. Shah IA, Whiting PH, Omar G, Ormerod AD, Burke MD. The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin. Br J Dermatol 1993;129:395-8.
89. Abdel-Rahman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997;31:445-56.
90. Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327-9.
91. Navakova I, Donnelly P, DeWitte T, De Pauw B, Boezeman J, Veltman G. Itraconazole and cyclosporin nephrotoxicity. Lancet 1987;2: 920-1.
92. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
93. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995;33:134-5.
94. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16:400-3.
95. Yeh JH, Soo S-C, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole (letter). BMJ 1990;301:669.
96. Pohjola-Sintonen S, Viitasalo M, Toivonen L. Itraconazole prevents terfenadine metabolism and increases risk of torsade de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3.
97. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994;27:1-5.
98. Interactions with astemizole. Int Pharm J 1993;7:10.
99. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14:165-74.
100. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993;9:309-11.
101. Blum RA, D'Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, Gardner MJ, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7.
102. 2 blockers. J Clin Pharmacol 1997;37:535-40.
103. Sahai J, Gallicano K, Pakuts A. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994;51:1014-8.
104. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR, Fluconazole and enhanced effect of rifabutin prophylaxis (letter). N Engl J Med 1994;330:1316.
105. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993;13:508-9.
106. Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993;153:102-4.
107. Touchette MA, Chandrasekar PH, Milad MA, Edwards DJ. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol 1992;34:75-8.
108. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420-5.
109. Apseloff G, Hilligoss DM, Gardner MJ, Henry EB, Inskeep PB, Gerber N, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358-61.
110. Marchetti A, Piech CT, McGhan WF, Neugut AI, Smith BT. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Therapeut 1996;18:757-77.
111. Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F, The Onychomycosis Study Group. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994;130(suppl 43):35-44.
112. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994;130(suppl 43):32-4.
113. Davis R, Balfour JA. Terbinafine: a pharmacoeconomic evaluation of its use in superficial fungal infections. PharmacoEconomics 1995;8: 253-69.
114. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used in the US for the treatment of dermatophyte onychomycosis of the toenails (abstract). Proceedings of the American Academy of Dermatology 55th Annual Meeting, March 21-26, 1997, San Francisco, CA.